OPGN earnings

Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 f

ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details       U.S. Dial-in Number:   1-877-704-4453       International Dial-in Number: 1-201-389-0920      Webcast:   https://viavid.webcasts.com/starthere.jsp?ei=1618010&tp_key=fc7c8907d6  Re

Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher HealthcareMet all remaining key milestones of the FIND collaboration for Unyvero A30Management conference call scheduled for May 15, 2023, at 4:30 p.m. EST ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 20

ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its first quarter 2023 financial results after the close of the U.S. financial markets on Monday, May, 15th, 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call DetailsU.S. Dial-in Number:International Dial-in Number:Webcast: 1-877-704-44531-201-389-0920https://viavid.webcasts.com/starthere.jsp?ei=1611539&tp_key=76976884dc  Replay Details U.S. Dial-in Number:

ROCKVILLE, Md., March 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its fourth quarter and full year 2022 financial results after the close of the U.S. financial markets on Wednesday, March 29th, 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details U.S. Dial-in Number:1-877-704-4453 International Dial-in Number:1-201-389-0920 Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1595064&tp_key=d21054e901  Conference I

Completes first two commercial customer installations for Acuitas AMR Gene PanelOpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with FIND for the Unyvero A30 RQ platformElects Yvonne Schlaeppi as new, independent non-executive director to the boardManagement conference call scheduled for November 10, 2022, at 4:30 p.m. EST ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2022 financial and operating results. Managemen

ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Standard Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details  U.S. Dial-in Number:1-877-704-4453 International Dial-in Number:1-201-389-0920 Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1569725&tp_key=91a31a2b1f Conference ID:1373

Total Q2 2022 revenues of $1.0 million with product sales a key growth driverFirst two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022Requested additional 180-day period to regain compliance with Nasdaq minimum bid price ruleManagement conference call scheduled for August 11th, 2022, at 4:30 p.m. EDT ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter 2022 financial and operating results. Management will host an investor call to discuss quarter

ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2022 financial results after the close of the U.S. financial markets on Thursday, August 11th, 2022. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call DetailsU.S. Dial-in Number:1-877-704-4453International Dial-in Number:1-201-389-0920Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1556114&tp_key=e1546ec0f5Conference ID:13730742 Replay De

Total Q1 2022 revenues of $0.5 millionCash position of approximately $30.7 million to reach into Q1-2023 Management conference call scheduled for May 12, 2022, at 4:30 p.m. EDT ROCKVILLE, Md., May 12, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update. "We are excited about our 2022 progress to date, as we continue to achieve our key milestones," said Oliver Schacht, Presid

ROCKVILLE, Md., April 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its first quarter 2022 financial results after the close of the U.S. financial markets on Thursday, May 12th, 2022. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details U.S. Dial-in Number:1-877-704-4453International Dial-in Number:1-201-389-0920Webcast:https://services.choruscall.com/mediaframe/webcast.html?webcastid=n37DadqyConference ID:13729189 Replay

Total revenue for 2021 was approximately $4.3 millionStrong total cash position of approximately $36.1 million as of December 31, 2021, up significantly from $13.4 million at year-end 2020Conference call to be held March 29, 2022 at 4:30 p.m. EDT ROCKVILLE, Md., March 29, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2021 and full-year 2021 financial and operating results and provided a business update. OpGen's revenue for the fourth quarter of 2021 was approximately $1.43 million, a 5% increas

ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its fourth quarter and full year 2021 financial results after the close of the U.S. financial markets on Tuesday, March 29th, 2022. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details U.S. Dial-in Number:1-877-705-6003International Dial-in Number:1-201-493-6725Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1525984&tp_key=2d6460e1c0Conference ID:1372

ROCKVILLE, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its third quarter 2021 financial results after the close of the U.S. financial markets on Thursday, November 11, 2021. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details U.S. Dial-in Number:1-877-705-6003International Dial-in Number:1-201-493-6725Webcast:http://public.viavid.com/index.php?id=146838 Conference ID:13723808  Replay Details U.S. Dial-in Numbe

Total Revenue for Q2 2021 was approximately $0.8 millionCash as of June 30, 2021 was approximately $31.2 million, up significantly from the $13.4 million at year-end 2020 Conference call to be held at 4:30 p.m. Eastern Daylight Savings Time today ROCKVILLE, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its financial and operating results for the three and six months ended June 30, 2021 and provided a business update. Total OpGen revenue for the second quarter of 2021 was approximately $0.8 million, down 32%

ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2021 financial results after the close of the U.S. financial markets on Thursday, August 12, 2021. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call DetailsU.S. Dial-in Number:1-800-458-4121International Dial-in Number:1-323-794-2093Webcast:http://public.viavid.com/index.php?id=146054Conference ID:7301173  Replay DetailsU.S. Dial-in Number:1-8